ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive: TKI resistance mediated by BCR-ABL gene amplifications and BCR-ABL kinase domain mutations frequently occurs in CML patients and neither the second nor the third generation of TKIs conquers it completely33.